Navigation Links
NeuroSigma Announces FDA Approval to Commence Phase III Trial
Date:7/29/2013

LOS ANGELES, July 29, 2013 /PRNewswire/ -- NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device Exemption (IDE) application to commence a Phase III pivotal trial of the Monarch™ eTNS™ System for treatment of drug resistant epilepsy.  The Company is planning to conduct a multi-center trial at leading medical institutions in the U.S., Europe and Canada.  The objective of the study is to evaluate the safety and effectiveness of the device and provide the basis for a Pre‐Market Approval (PMA) application to the FDA.

In earlier Phase 1 and Phase 2 clinical trials of external Trigeminal Nerve Stimulation (eTNS), over 40% of patients treated showed a 50% or greater reduction in seizures.  "We are eager to take this next key step in the regulatory approval process of eTNS in the United States," said Leon Ekchian, Ph.D., President and CEO of NeuroSigma.  "We believe a safe, non-invasive and affordable alternative to pharmaceuticals and invasive treatments is urgently needed by the 50-million people with epilepsy worldwide."

The Monarch eTNS System is currently available with a physician's prescription in the European Union and Canada as adjunctive treatment of epilepsy and depression, for adults and children 9 years and older.

About TNS and The Monarch eTNS System

The Monarch eTNS System is c
'/>"/>

SOURCE NeuroSigma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
2. NeuroSigma Receives Global Quality Control Certification
3. NeuroSigma Receives CE Certification
4. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
5. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
6. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
7. NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder
8. NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression
9. NeuroSigma Announces Debut of Its Monarch eTNS System in Canada
10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 /PRNewswire/ ... Auxilium Pharmaceuticals, Inc. today announced that the Committee for ... Medicines Agency (EMA) has adopted a positive opinion for ... treatment of adult men with Peyronie,s disease with a ... degrees at the start of therapy. The ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... 30 CEL-SCI Corporation,(Amex: CVM ) announced that ... Rodman & Renshaw 9th Annual Healthcare Conference being,held at ... The presentation,will be focused on its Phase III cancer ... to become a new first line standard of,care treatment ...
... Oct. 29 As a follow up to ... eliminating,Methicillin resistant Staphylococcus aureus (MRSA), the Association for,Professionals ... days next,month in Atlanta to discuss new developments ... "MRSA: The Call to Action 1 Year ...
Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2APIC Conference to Discuss MRSA Elimination 2
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
(Date:12/24/2014)... The 2014 Market Research Report on ... research report on COC industry. For an overview ... its definition, classification, application, industry chain structure, industry ... also presents product specification, manufacturing process, and product ... technology and applications. Analysis also covers upstream raw ...
(Date:12/24/2014)... December 24, 2014 Dental implants benefit ... a tooth replacement. They offer the strongest and most ... over other forms of tooth replacement. They will never ... the adjacent teeth for support, and they prevent the ... been told that they are not suitable candidates for ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2
... A new study shows that smokers who think that they might ... a “ light “ or “ mild “ cigarette // might ... reduction in nicotine is minimal, and in the end, the light ... Previous studies have shown that low-yield cigarettes can be just as ...
... a person’s risk of developing dementia later in life, a ... recent study conducted, researchers followed nearly 1,500 participants for more ... middle age were twice as likely to develop dementia later ... blood pressure in middle age were six-times more likely to ...
... can avoid the risk of stroke by eating broiled or baked ... to four// times a week had 28% less risk ... who ate fish less than once a month. And people who ... their risk was lowered by 31%. However the fish cooked had ...
... time, a drug seems to slightly delay the progress ... studies have shown that without treatment, about 10 percent ... will progress to Alzheimer’s disease each year. However, not ... ,Researchers compared vitamin E, the Alzheimer’s treatment drug ...
... patients fare better after having a procedure to open clogged ... from a recent study. The study, conducted in Taiwan, looked ... of about 870 men and about 160 women who underwent ... While both sexes had about the same success rate for ...
... lining the uterus grow outside of the uterus and ... The condition can cause bleeding, pain and discomfort. Women ... to suffer from the painful condition known as endometriosis, ... diagnosed with endometriosis, comparing their results to 504 other ...
Cached Medicine News:
Pneumatic oscillating saw, 35k cpm, available with various hose connector styles....
... hand throttle. Accepts all 1000 and 2000 ... hose 9000-000, or existing hose with Microaire ... or existing hose with Linvatec/Hall connector (1000-200). ... hose with 3M connector (1000-300). , 10ft ...
Pneumatic extended oscillating saw, 35k cpm, available with various hose connector styles....
Pneumatic pencil-grip wire driver, 3000 rpm, available with various hose connector styles....
Medicine Products: